GlassScriptPhysician profile
James Henry Jen Kin
NPI 1548238819
$15,944.73
in general payments reported to CMS, 2019-2025
30 companies · $793 in 2025
The $793 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $1,305 · 2021: $2,668 · 2022: $2,843 · 2023: $3,477 · 2024: $3,773 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,043.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,084.57 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,930.22 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,737.15 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $1,735.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,287.03 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,269.09 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,119.72 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,071.08 | 2020-2025 | Ingrezza |
| Lundbeck LLC | $893.49 | 2019-2025 | Rexulti |
| Allergan, INC. | $613.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $385.24 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $217.96 | 2023-2024 | Auvelity |
| Almatica Pharma LLC | $195.53 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $170.49 | 2022-2024 | Azstarys |
| Tris Pharma INC | $168.61 | 2023-2024 | Dyanavel Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $151.76 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $147.57 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $107.91 | 2021-2022 | |
| Indivior INC. | $102.39 | 2019-2023 | Perseris |
| Adlon Therapeutics L.P. | $92.99 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $86.70 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $85.51 | 2020-2024 | Aplenzin, Wellbutrin |
| Sage Therapeutics, LLC | $72.57 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $50.69 | 2024 | |
| Neuronetics, INC. | $46.70 | 2022 | |
| Noven Therapeutics, LLC | $41.09 | 2021-2024 | Xelstrym |
| Sun Pharmaceutical Industries INC. | $21.85 | 2021 | |
| Livanova USA, INC. | $21.69 | 2020 | |
| Merck Sharp & Dohme LLC | $20.76 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jen Kin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.